Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring Jun 25 | 2020Menarini Launches GlucoMen CGM in EuropePurchase Blast
$599
Posted in: GLP-1RA, Glucagon Jun 24 | 2020Lilly Launches Educational Initiative; Thane Wettig Joins FibroGen; Tandem Acquires Sugarmate; BI Doses First Patient in Ph2 Dual-agonist Trial; IM Therapeutics Doses First Patient with Novel T1DM TherapyPurchase Blast
$599
Posted in: Insulin Delivery Jun 23 | 2020Companion Medical's InPen Approved in Peds; BrightInsight Secures $40M Series B FundingPurchase Blast
$599
Posted in: GLP-1RA, SGLT2i Jun 22 | 2020DAPA-HF CHMP Opinion This Week?; CHMP Agenda June 22-25Purchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Jun 22 | 2020Autolus Ph1/2 ALLCAR19 Results and EHA 2020 Investor Call SummaryPurchase Blast
$599
Posted in: Glucose Monitoring Jun 22 | 2020Libre 2 AID Compatibility Issue Worse Than ExpectedPurchase Blast
$599
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jun 19 | 2020Ziopharm Appoints Carl June as Chairman of Scientific Advisory BoardPurchase Blast
$599
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jun 19 | 2020Thoughts on Ziopharm’s CAR-T And TCR-T Program Updates, Including Their Rapid Personalized Manufacturing Technology; Q1 2020 CallPurchase Blast
$599
Posted in: Insulin Delivery Jun 19 | 2020Roche Sues Insulet for Omnipod RoyaltiesPurchase Blast
$599
Posted in: GLP-1RA, Other Jun 18 | 2020Novo Reports Impressive AM833 Ph2 and AM833+sema Ph1 Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jun 18 | 2020Xeris Ph2 Pramlintide+insulin Co-formulation Topline ResultsPurchase Blast
$599
Posted in: Insulin Delivery Jun 17 | 2020Tandem Control-IQ Approved in Peds Down to 6 Years of AgePurchase Blast$599
Posted in: Glucose Monitoring Jun 17 | 2020Abbott Libre 2 Promotion Takes Shots at Dexcom G6; Libre 2 Digital DTC InitiatedPurchase Blast
$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jun 17 | 2020Novartis Discusses Their Activated Rapid Manufacturing Program and Kymriah in the Community SettingPurchase Blast
$599
Posted in: Glucose Monitoring, SGLT2i Jun 16 | 2020VERTIS-CV Questions Remain; Dexcom Partnered for COVID-19 Remote Monitoring; New Libre RWE; Nemaura Continues PR Blitz; ADA Key Press Releases (June 16)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, Glucagon, Glucose Monitoring, Insulin Delivery Jun 15 | 2020Dapa Reduces Progression to T2DM; Teplizumab Continues to Delay T1DM Onset; Arecor AT247 Faster than Fiasp; ADA Key Press Releases (June 15)Purchase Blast
$599
Posted in: Bolus Insulin Jun 15 | 2020Lilly’s Lyumjev FDA Approved (ultra-rapid lispro)Purchase Blast
$599
Posted in: Glucose Monitoring Jun 15 | 2020Libre 2 US Approval Was Worth the Wait for Abbott, but Not Its Pump PartnersPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
